Join the club for FREE to access the whole archive and other member benefits.

AbbVie and Calico extends their collab up to 2025 with a $1 billion deal

Supports ageing research and advancing early-stage projects to phase 2 trials over the next decade


Key points from article :

Seven years ago, AbbVie penned an early-stage deal with Google/Alphabet’s life sciences division Calico.

This deal in 2014 focused on age-related diseases, including neurodegeneration and cancer.

Back in 2018, the pair signed their first extension, putting in an extra $1 billion to keep it going.

Today, another $1 billion goes into the pot, and another extension, bringing the collab from 2022 to 2025.

Calico is responsible for research and early development and will push the projects into phase 2a.

AbbVie will continue its early R&D efforts and has an option to manage late-stage development and the sales side.

Since the collaboration, researchers have produced more than two dozen early-stage programs in oncology and neuroscience.

Its lead immuno-oncology target is currently in phase 1 studies which act at multiple steps in the cancer immunity cycle.

“..could yield both novel insights into the biology of aging and first-in-class targets for age-related diseases," - Calico CEO Arthur Levinson.

Mentioned in this article:

Click on resource name for more details.


Pharmaceutical research and development.

Arthur D. Levinson

CEO of Calico, Chairman of Apple Inc. and former CEO and chairman of Genentech.


Combating aging and associated diseases. An Alphabet (Google) subsidiary.

Topics mentioned on this page:
Investments, Cancer